To date, only one phase II randomized controlled clinical trial (CTONG 1901) has directly compared the efficacy of two PD-1 inhibitors (sintilimab and pembrolizumab) as first-line treatments for advanced NSCLC (Liu et al., 2022). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.